



Biotech Daily

Friday March 11, 2016

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: ACTINOGEN UP 15.5%, PRANA DOWN 10.5%**
- * **AVITA SIGNS SINOPHARM FOR CHINA DISTRIBUTION**
- * **S&P INDICES: 5 BIOTECHS PROMOTED, 5 DEMOTED**
- * **LISTEN AND LEARN JOINS AVEXA TALI EVALUATION**
- * **MEDIBIO ACQUIRES US, CANADA UNIVERSITY DATA SETS**
- * **NOVOGEN WITHDRAWS 61% DIRECTORS POOL HIKE RESOLUTION**
- * **CLINUVEL REQUESTS CAPITAL RAISING TRADING HALT**
- * **RESAPP PLEADS SCHULTZ, NEWS, FDA MEETING TO ASX 44% QUERY**
- * **GENETIC SIGNATURES 18.4m ESCROW SHARES TO BE RELEASED**

MARKET REPORT

The Australian stock market was up 0.32 percent on Friday March 11, 2016 with the ASX200 up 16.3 points to 5,166.4 points.

Fifteen of the Biotech Daily Top 40 stocks were up, 11 fell, eight traded unchanged and six were untraded. All three Big Caps were up.

Actinogen was the best for the second day in a row, on investor presentations, up 1.1 cents or 15.5 percent to 8.2 cents with 5.1 million shares traded, followed by Admedus up 12.8 percent to 53 cents and Prima up 12.5 percent to 4.5 cents.

Cellmid and Viralytics climbed more than 10 percent; Avita was up 6.1 percent; Compumedics improved 4.2 percent; Atcor, Living Cell, Medical Developments, Pharmaxis, Pro Medicus and Resmed rose more than two percent; Osprey and Polynovo were up more than one percent; with Cochlear, CSL and Sirtex up less than one percent.

Prana led the falls for the second day in a row, down 0.8 cents or 10.5 percent to 6.8 cents with 446,677 shares traded.

Biotron and Nanosonics fell more than four percent; Anteo, IDT, Impedimed and Oncosil were down more than three percent; Acrux shed 2.3 percent; with Bionomics, Mesoblast and Starpharma down more than one percent.

AVITA MEDICAL

Avita says it has an exclusive distribution deal for China its leading healthcare group, Sinopharm.

Avita said that the deal grants exclusive distribution to Sinopharm of the Avita range of medical devices for burns, chronic wounds and aesthetic conditions.

The company said that it had been active in China for five years, with sales in the main cities of Beijing, Shanghai and Guangzhou, primarily focussed on plastic surgery and repigmentation.

Avita said that Sinopharm was involved in distribution, retail sales, research and development and the manufacture of health care-related products, generating sales of RMB200 billion (\$A41 billion) in 2014.

The company said that about 3.4 million people were hospitalized with burns each year in China and about 1.4 million had vitiligo, with scope for expansion into cosmetic surgery and chronic wounds.

Avita said it would provide clinical support to the Sinopharm sales team and agent network to help with interactions with medical professionals, as well as backing new research into Avita's regenerative medicine approach.

The company said that last year investigators in Guangzhou delivered the first randomized controlled trial to use the Recell device on chronic wounds, which showed superior wound closure.

Avita said that the Sinopharm deal was the eighth territory to be signed in the past three months.

Avita was up 0.6 cents or 6.1 percent to 10.5 cents with 6.7 million shares traded.

STANDARD & POOR'S DOW JONES INDICES

Standard & Poor's Dow Jones Indices say that Acrux will be removed from the S&P ASX300 after the market closes on March 18, 2016.

Standard & Poor's said that Medical Developments, Polynovo, Prima Biomed, Reva and Viralytics would be added to the All Ordinaries Index, while Anteo, GI Dynamics, Prana and Unilife would be removed from the Index.

AVEXA

Avexa says it has a heads of agreement with the Melbourne-based Listen And Learn Centre to evaluate the Tali diagnostic for children with intellectual disabilities.

Avexa said that the agreement meant that the Centre would join Monash University, Grey Innovation and Torus Games in the trialling and evaluation of the Tali technology.

In February, Avexa completed the acquisition of Tali, which was developed at Monash University (BD: Oct 12, 2015; Feb 15, 2016).

Today, Avexa said the Listen And Learn Centre was the first to adopt the Tali technology and the evaluation would "further align the technology with the needs of the market and clinical patient requirements in game development and clinical trial workshops".

Listen And Learn Centre founder Martha Mack said that Tali would "enable psychologists, speech and language pathologists, occupational therapists and educators to add a scientifically validated treatment option to their clinical and educational toolbox, thereby offering an additional evidence-based treatment to existing behavior management approaches or pharmaceutical products in the treatment of those suffering from attentional disabilities".

Avexa was unchanged at 3.9 cents.

MEDIBIO

Medibio says that four US universities have provided databases of physiological files to undertake joint research and development into mental health conditions.

Medibio said that the databases from the Johns Hopkins School of Medicine, Emory University, Washington University and Ottawa's Royal Institute of Mental Health Research "dramatically increases" its research and development capabilities and would expand potential commercial offerings for its "digital mental health platform".

Previously, Medibio said it was developing a heart rate diagnostic for depression and other mental illnesses (BD: Feb 6, 2015).

Today, Medibio said it had more than 10,000 overnight physiological data files including electro-encephalograms, electro-cardiograms and other biometric data files for analysis by its digital mental health platform, which "more than trebles the size of Medibio's repository of data files" and it expected the receipt of additional data in the coming months.

The company said the data meant it could generate proxy-clinical trial outcomes and meta-data analyses from more than 15,000 patients retrospectively and refine advanced machine learning techniques to accelerate the optimisation of its algorithms.

Medibio said that data from 900 University of Ottawa files would be used for an independent validation study of its depression test and a second study which was underway would develop a sleep algorithm to distinguish between the five stages of sleep. Medibio said that data included a set of 800 patients, comprising 400 with myocardial infarction and depression and 400 with myocardial infarction and without depression, providing "the opportunity to explore analytics relating to the comorbidity between depression and heart disease".

The company said the third near-term project underway would use the additional data to update its existing stress algorithm and would "double the number of stress categories" from mild, moderate and serious to six categories, offering a more effective assessment and monitoring of stress levels.

Medibio was unchanged at 20 cents.

NOVOGEN

Novogen says it will withdraw an extraordinary general meeting resolution to increase the directors remuneration pool by 60.7 percent to \$900,000.

In February, Novogen proposed to increase the maximum aggregate non-executive directors' remuneration from \$560,000, saying it had not increased since the 2005 annual general meeting (BD: Feb 16, 2016).

Today, the company said it was "inopportune to propose the resolution at this time".

"Whilst there had been no intention of using the increased cap, the board accepts the concern this has caused shareholders," Novogen said.

Novogen said in February that the meeting would vote to grant chief executive officer Dr James Garner 7,500,000 options and vote on the election of director of Iain Ross.

The meeting will be held at Level 5, 20 George Street, Hornsby, Sydney on March 18, 2016 at 10.30am (AEDT).

Novogen was unchanged at 11.5 cents.

CLINUVEL PHARMACEUTICALS

Clinuvel has requested a trading halt "regarding a proposed capital raising".

Trading will resume on March 15, 2016 or on an earlier announcement.

Clinuvel last traded at \$3.30.

RESAPP HEALTH

Resapp has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price climbed 44.4 percent from 18 cents on March 7 to 26 cents on March 11, 2016, and noted an increase in trading volumes.

Resapp said that on March 7 it announced a non-binding agreement with an unnamed humanitarian organisation and Uniquet to test its pneumonia diagnostic tool in the developing world.

The company said that chief executive officer Dr Tony Keating was in the US presenting to investors, partners and potential study collaborators and a pre-submission meeting was held with the US Food and Drug Administration this morning.

Resapp closed up 3.5 cents or 14.9 percent to 27 cents with 23.3 million shares traded.

GENETIC SIGNATURES

Genetic Signatures says that 18,434,065 shares held in voluntary escrow by Asia Union Investments, will be released from escrow on March 30, 2016.

Genetic Signatures said that it had a total of 72,688,990 shares quoted on the ASX, including 49,589,010 shares, 4,425,000 employee share plan shares, 2,872,355 shares in ASX escrow for 24 months and 15,802,625 shares in voluntary escrow for 24 months.

Genetic Signatures was up 3.5 cents or six percent to 62 cents.